Economics at your fingertips  

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood

Seamus Kent, Frauke Becker, Talitha Feenstra, An Tran-Duy, Iryna Schlackow, Michelle Tew, Ping Zhang, Wen Ye, Shi Lizheng, William Herman, Phil McEwan, Wendelin Schramm, Alastair Gray (), Jose Leal, Mark Lamotte, Michael Willis, Andrew J Palmer and Philip Clarke ()
Additional contact information
Seamus Kent: University of Oxford
Frauke Becker: University of Oxford
Talitha Feenstra: National Institute for Public Health and the Environment (RIVM), Centre for Nutrition, Prevention and Health Services Research
An Tran-Duy: The University of Melbourne
Iryna Schlackow: University of Oxford
Michelle Tew: The University of Melbourne
Ping Zhang: Centres for Disease Control and Prevention
Wen Ye: University of Michigan
Shi Lizheng: Tulane University
William Herman: University of Michigan
Phil McEwan: Swansea University
Wendelin Schramm: GECKO Institute, Heilbronn University
Jose Leal: University of Oxford
Mark Lamotte: IQVIA
Michael Willis: The Swedish Institute for Health Economics
Andrew J Palmer: The University of Melbourne
Philip Clarke: University of Oxford

PharmacoEconomics, 2019, vol. 37, issue 11, No 2, 1305-1312

Abstract: Abstract Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry ( Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.

Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2) Track citations by RSS feed

Downloads: (external link) Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Ordering information: This journal article can be ordered from

DOI: 10.1007/s40273-019-00825-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Page updated 2020-11-11
Handle: RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00825-1